Navigation Links
EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
Date:10/22/2007

TARRYTOWN, N.Y., Oct. 22 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Dr. Ben Tseng, Chief Scientific Officer, will present the results of studies examining the combination of EPC2407 with cancer therapeutics in preclinical animal models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA on October 24, 2007. EPC2407 is EpiCept's novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas that recently completed enrollment in a Phase Ia single agent trial.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

The preclinical studies examined the effectiveness of combining EPC2407 with an anti-angiogenesis inhibitor, Avastin(R) or Sutent(R), or with the chemotherapeutic agent cisplatin. EPC2407 was administered in combination with a cancer therapeutic agent in mouse xenograft models of human non-small cell lung carcinomas and human breast carcinomas. These studies indicated significantly enhanced anti-tumor activity when EPC2407 was added to the therapeutic regimen, compared with either agent administered alone, which resulted in increased median survival and number of tumor-free animals well after the end of treatment (>2.5 months). The results demonstrated additive to synergistic activity when EPC2407 is used in combination with these cancer therapeutics.

These results strongly support the clinical testing of EPC2407 in combination with different anti-cancer agents. Advancement of EPC2407 in clinical trials to Phase Ib combination studies is planned to initiate in early 2008.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. EpiCept Accelerates Development of Phase I Clinical Study for Cancer
2. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
3. Researchers Present Ways To Reduce The Risk Of Dementia
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
6. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
7. Drug Reactions First Present Themselves In The Mouth
8. Reminiscing Into The Past Makes You Dissatisfied With The Present
9. Living In The Past Indicates Dissatisfaction With Present
10. Movies Represent Coma In A Wrong Way
11. Onchocerciasis: Presentation And Treatment

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...tional Ambassador ,, WHITE PLAINS, N.Y., Nov....ston, Fla., was born so early and with so many und...her he would survive -- or if he would ever walk, ... March of Dimes 2010 National Ambassador. ,, J...inutes of motherhood and I was completely devastat...
(Date:11/9/2009)...this is so, however , , MONDAY, Nov. 9...h very dense breasts have a higher risk of cancer ...ws. , Breast density has already been linked wi...and experts have suspected that very dense breasts...cancer recurrence at the site of the original canc...
(Date:11/9/2009)...ewswire/ -- At a time when the 250,000+ eligible M...rned about finding affordable health insurance, th.... ,, The Today,s Options® Preferred Provid...ides a cost-effective and comprehensive alternativ...an. People with Medicare can choose to sign up fo...
(Date:11/9/2009)...o move lab findings into human therapy for difficu...e damage ,, ANN ARBOR, Mich., Nov. 9 /PRNewswi...f Michigan Department of Neurology have received a... neuropathic pain, a difficult-to-treat condition ...e to nerve without obvious tissue injury. ,, In...
(Date:11/9/2009)...tion industry, respiratory disease, often leading ... major public health concern. Studies led by Debo...ch,s School of Construction, have shown that speci... reducing the dust that causes these health hazard...ology remains very low. , To find out why, Young...
Breaking Medicine News(10 mins):Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2Health News:U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3
...roll out Lumina to the Georgia Banker,s Insurance ...., a wholly owned subsidiary of the Georgia Banker...oday a partnership with Atlanta-based North Star H...ates wellness, preventive health, disease manageme...
...Highland Good Steward Management ("HGSM") today an..., a Connecticut-based investment adviser, as a sub...M"), an Alabama-based investment adviser. HGSM f... of K2, said, "K2 and Highland Good Steward Manage...
...rce of Antioxidant Melatonin , , LANSING, Mich., ...n have the unfortunate side effect of disrupting y...t losing even one hour of sleep may affect us for ... the body in small amounts, melatonin plays a role...
...antly improve the safety of methadone, a drug wide...in and other opioid drugs, according to researcher...t. Louis and the University of Washington in Seatt...have been making it difficult for physicians to un...
...hat aspirin inhibited the growth of H. pylori in...d the activity of virulence factors of H. pylori ...y of H. pylori to antimicrlbials including metro...Hospital of China addressed this issue and their r...
...cal example of a malabsorption syndrome conferring...luding folate and vitamin B12. Hyperhomocysteinemi...newly diagnosed coeliac disease than healthy contr...on homocysteine levels in patients with coeliac di...
Other Medicine News:Health News:Paragon Benefits, Inc. Selects North Star Health for Data Analysis and Cost Management Reporting 2Health News:K2 Advisors Named Investment Advisor by Highland Good Steward Management 2Health News:'America's Super Fruit' May Help Reset Body Clock 2Health News:'America's Super Fruit' May Help Reset Body Clock 3Health News:New information points to safer methadone use for treatment of pain and addiction 2Health News:New information points to safer methadone use for treatment of pain and addiction 3Health News:New information points to safer methadone use for treatment of pain and addiction 4Health News:Why does aspirin increase the susceptibility of Helicobacter pylori to antimicrobials? 2Health News:Are vitamin supplements effective in celiac disease patients? 2
(Date:11/9/2009)...swire-Asia/ -- Chindex International, Inc.,("Chind...can provider of Western,healthcare products and se...nounced results for the second quarter and first h.... , , Financial Highlights:, -- Revenue in ...n, flat on, a year over year basis;, -- N...
(Date:11/9/2009)...wire-FirstCall/ -- Caliper Life Sciences, Inc. (Na...vices for drug discovery and life sciences researc...ances and Services (CDAS) unit has been awarded a ...contract with the Environmental Protection Agency ...is new task order increases the cumulative funding...
(Date:11/6/2009)...-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC B...usly approved reverse split of its common stock wi...Nov. 9, 2009 on a 1-for-15 split-adjusted basis. O...r the new symbol OXBT. The stock also will have a ...mes effective. ,, "This reverse split was overw...
Breaking Medicine Technology:Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 2Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 3Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 4Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 5Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 6Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 7Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 8Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 9Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 10Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 11Caliper Awarded New Task Order for EPA ToxCast Program 2Caliper Awarded New Task Order for EPA ToxCast Program 3Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 53019 1Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 53019 2Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 53019 3Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe 53019 4FRC Action Launches TV Ad Campaign On Government Health Care Takeover 53017 1FRC Action Launches TV Ad Campaign On Government Health Care Takeover 53017 2Fujitsu Expands Support for Ethernet Networks With New Additions to XG Switch Product Line 9403 1Fujitsu Expands Support for Ethernet Networks With New Additions to XG Switch Product Line 9403 2Fujitsu Expands Support for Ethernet Networks With New Additions to XG Switch Product Line 9403 3
...patient receives ,hidden scar, procedure; Pediatri...m single port surgery with RealHand HD ... July 28 Novare Surgical Systems,announced the su...port,splenectomy, using RealHand HD instruments. T...s doing very well and one day after his surgery wa...
...-Scale Analyses Have Conflicting Results -, CHICA... and thinking processes among placebo groups in Al... ability to show the effectiveness,of new Alzheime...day at the,2008 Alzheimer,s Association Internatio...in Chicago., Alzheimer clinical trials seek to sh...
Other Medicine Technology:Novare Announces Completion of First Pediatric Single Port Spleen Removal Using RealHand(R) HD Instruments 2Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 2Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 3Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 4Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 5
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
Medicine Products: